National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening - 24/04/13
Doi : 10.1016/j.jaad.2008.01.006
Alexa B. Kimball, MD, MPH a, ⁎ 
, Dafna Gladman, MD b, Joel M. Gelfand, MD, MSCE c, Kenneth Gordon, MD d, Elizabeth J. Horn, PhD, MBI e, Neil J. Korman, MD, PhD f, Gretchen Korver, MD, PhD g, Gerald G. Krueger, MD g, Bruce E. Strober, MD, PhD h, Mark G. Lebwohl, MD i
, Dafna Gladman, MD b, Joel M. Gelfand, MD, MSCE c, Kenneth Gordon, MD d, Elizabeth J. Horn, PhD, MBI e, Neil J. Korman, MD, PhD f, Gretchen Korver, MD, PhD g, Gerald G. Krueger, MD g, Bruce E. Strober, MD, PhD h, Mark G. Lebwohl, MD iNational Psoriasis Foundation
a Department of Dermatology at Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
g Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah
i Department of Dermatology, Mount Sinai School of Medicine, New York, New York
b Department of Dermatology, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Canada
c Department of Dermatology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania
d Division of Dermatology, Evanston Northwestern Healthcare, Skokie, Illinois
e Division of Dermatology, National Psoriasis Foundation, Portland, Oregon
f Division of Dermatology, Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
h Ronald O. Perelman Department of Dermatology, New York University, New York, New York
Reprint requests: Alexa B. Kimball, MD, Massachusetts General and Brigham and Women’s Hospitals, 50 Staniford St, #246, Boston, MA 02114.Abstract |
There have been several articles and reports in recent months about comorbidities and risks that affect psoriasis patients in addition to their underlying disease. This piece reviews the current literature and begins to address what should be done with this new information by updating the clinician about what health screening tests, preventative exams, and referrals should be considered in this population.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by the National Psoriasis Foundation and the National Institutes of Health grant K23AR051125-01, National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand). |
|
| Disclosures: Dr Kimball is an investigator and consultant for Abbott, Centocor, and Amgen, and receives funding for a fellowship from Centocor. Dr Gladman is a consultant to Abbott, Amgen, Centocor, Schering-Plough, and Wyeth and received unrestricted research grant support from Abbott Canada, Amgen-Wyeth Canada, Schering Plough Canada, Pfizer Canada, and Wyeth Global. Dr Gelfand is an investigator for or receives grant support from Amgen, Abbott, and Centocor. He is a consultant for Amgen, Centocor, and Genentech and his practice provides phototherapies. Dr Gordon has received research support and honoraria from Abbott, Amgen, and Centocor. Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen and Wyeth, Astellas Pharma, Inc, Barrier Therapeuics, Beiersdorf, Centocor, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Neutrogena, Photomedex, Stiefel Laboratories, and Warner Chilcott. Dr Korman is an investigator for or receives grant support from Abbott Laboratories, Amgen, Astellas, Biogen Idec, Centocor, Genentech, Genmab, Novartis, Peplin, and Seattle Genetics. He is also a speaker or consultant for Abbott Laboratories, Amgen, Genentech, Genmab, Novartis, and Peplin, and his practice provides phototherapy services. Dr Korver has received some fellowship support from Amgen and Centocor. Dr Krueger is a consultant or advisory board member for Abbott, Almirall, Alza, Amgen, Astellas, Barrier Therapeutics, Boehringer Ingleheim, Bristol Myers Squibb, Centocor, Connetics, Genentech, Genzyme, L’Oreal, Magen Biosciencs, MedaCorp, Medicis, Novartis, Schering Plough, Warner Chilcot, and ZARS. He owns equities and stock options in/from ZARS. Dr Krueger has received lecture fees from Abbott, Amgen, Astellas, Boehringer Ingleheim, Centocor, Connetics, and Warner Chilcott, and partial stipend support for a clinical research fellowship from Abbott, Amgen, and Centocor. Dr Strober is a speaker, advisor, and/or investigator for Amgen-Wyeth, Abbott, Centocor, Astellas, and Genentech. Dr Lebwohl is an investigator for Abbott Laboratories, Amgen, Astellas, Centocor, Connetics, Galderma, Genentech, 3M, Novartis, and Warner Chilcott. He is also a consultant for Abbott, Amgen, Astellas, BristolMyersSquibb, Centocor, Connetics, Galderma, Genentech, 3M, Novartis, Pfizer, and Warner Chilcott and speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, 3M, Novartis, PharmaDerm, and Warner Chilcott, and his practice provides phototherapy services. |
© 2008
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 58 - N° 6
P. 1031-1042 - juin 2008 Retour au numéro
Article précédent
- Nephrogenic systemic fibrosis is associated with transforming growth factor β and Smad without evidence of renin-angiotensin system involvement
- Brent Kelly, Matthew Petitt, Ramon Sanchez
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
- Dedee F. Murrell, Sarah Dick, A.R. Ahmed, Masayuki Amagai, Maria A. Barnadas, Luca Borradori, Jean-Claude Bystryn, Giuseppe Cianchini, Luis Diaz, David Fivenson, Russell Hall, Karen E. Harman, Takashi Hashimoto, Michael Hertl, Nico Hunzelmann, Pilar Iranzo, Pascal Joly, Marcel F. Jonkman, Yasuo Kitajima, Neil J. Korman, Linda K. Martin, Daniel Mimouni, Amit G. Pandya, Aimee S. Payne, David Rubenstein, Hiroshi Shimizu, Animesh A. Sinha, David Sirois, Detlef Zillikens, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?